Sugi Predict

Sugi Predict / Compounds / SCHEMBL488349

SCHEMBL488349

SCHEMBL488349

CNCC(O)CN1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ CARM1 Q86X55 11/20 0.59
▸ ATM Q13315 2/20 0.56
▸ MAPT P10636 1/20 0.56
▸ PRMT6 Q96LA8 3/20 0.50
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.46
▸ PRMT1 Q99873 1/20 0.43
▸ PRMT8 Q9NR22 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333351 1.00 MEN1 (0.60) MEN1KMT2ACARM1ATMMAPT
SCHEMBL4331083 1.00 MEN1 (0.60) MEN1KMT2ACARM1ATMMAPT
SCHEMBL16181815 0.98 MEN1 (0.64) MEN1KMT2ACARM1ATMMAPT
SCHEMBL3967935 0.83 CARM1 (0.60) MEN1KMT2ACARM1PRMT6HTT
SCHEMBL4482944 0.82 USP2 (0.67) CARM1ATMPRMT6SMN1; SMN2RECQL
SCHEMBL13043937 0.82 CARM1 (0.54) MEN1KMT2ACARM1ATMMAPT
SCHEMBL3738380 0.82 CARM1 (0.54) MEN1KMT2ACARM1ATMMAPT
SCHEMBL4482950 0.82 USP2 (0.67) CARM1ATMPRMT6SMN1; SMN2RECQL
SCHEMBL4488790 0.82 USP2 (0.67) CARM1ATMPRMT6SMN1; SMN2RECQL
SCHEMBL10608443 0.79 CARM1 (0.48) MEN1KMT2ACARM1ATMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536716-B1 AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-05-21 — — EP disclosed
EP-1603570-B9 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS SUGEN INC (US) 2013-10-23 — — EP disclosed
US-8426604-B2 Aminothiazolones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2013-04-23 — — US disclosed
EP-1603570-B1 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS SUGEN INC (US) 2013-01-23 — — EP disclosed
CN-102869660-A Aminothiazolones as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2013-01-09 — — CN disclosed
EP-2536716-A1 AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS Janssen Pharmaceutica, N.V. (BE) 2012-12-26 — — EP disclosed
EP-2476667-A2 Aminoheteroaryl compounds as protein kinase inhibitors Sugen, Inc. (US) 2012-07-18 — — EP disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
WO-2011103130-A1 AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-25 — — WO disclosed
US-20110200586-A1 AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-08-18 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 — — US disclosed
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. 2005-01-13 — — US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 — — US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 — — US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 — — EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 — — US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 MEN1 4419/4885KMT2A 1573/4885CARM1 1924/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 MEN1 4419/4885KMT2A 1573/4885CARM1 1924/4885
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer MET, ERBB2, CDK4 MEN1 783/4885KMT2A 430/4885CARM1 201/4885
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 MEN1 1141/4885KMT2A 1170/4885CARM1 269/4885
US-20110200586-A1 AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS ESR2, ESRRA, ESRRG MEN1 2511/4885KMT2A 1349/4885CARM1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.